Venous thrombosis/thromboembolism affects over 1 million Americans per year. Thrombus burden (size) predicts long-term outcome. Efforts to reduce venous thrombus burden with the development of new drugs could have a considerable impact on the US population. The defining characteristic of venous """"""""red"""""""" thrombi is their high red blood cell (RBC) content, which was traditionally thought to result from passive trapping of RBCs in the static fibrin clot. However, our new preliminary data indicate that RBCs are retained in clots via an active mechanism that requires the fibrin cross-linking enzyme, factor XIII (FXIII) The goal of this application is to determine the molecular mechanisms by which FXIII, fibrin(ogen), FXIII-mediated fibrin cross-linking, and RBCs contribute to venous thrombosis. Our overall hypotheses are that FXIII activity is required to retain RBCs in venous thrombi, and that blocking or reducing FXIII activity will reduce venous thrombus size. This hypothesis will be addressed in three Specific Aims: 1) Map the fibrinogen residues that mediate FXIII binding and determine the impact of FXIII activation and activity on fibrin network structure and stability, 2) Determine the contributions of blood components (FXIII, RBCs, and fibrinogen) to clot size in a whole blood milieu, and 3) Determine the effect of FXIII inhibitors on the formation and stability of venous thrombi. We will employ biochemical, genetic and pharmacologic tools in vitro and in vivo to define the FXIII-fibrinogen axis and determine the role of FXIII activity and RBC retention in venous thrombosis. Fibrin(ogen)-FXIII interactions will be examined using solution phase binding assays, microscopy, innovative fibrin analytical methods, and thromboelastography. Clot formation will be examined in reconstituted whole blood models using plasmas from healthy individuals and patients with a history of venous thrombosis. Thrombus formation and stability will be examined using venous thrombosis and thrombolysis models, immunohistochemistry, ultrasound imaging, and intravital microscopy. These studies will elucidate the biological role of FXIII activity in venous thrombosis, and define novel roles for fibrin(ogen) and RBCs in venous thrombus formation and stability. The study is highly innovative because it challenges the current paradigm that RBCs are passively trapped in static, fibrin- rich venous thrombi. The proposed research is clinically significant because it may reveal new strategies to reduce venous thrombosis in the US population.

Public Health Relevance

The proposed research is relevant to public health because it will reveal information about a novel mechanism that mediates venous thrombosis. Specifically, the work focuses on the incorporation of red blood cells in venous thrombi, and how red blood cell incorporation and venous thrombus size may be reduced to prevent thrombus formation. The project is relevant to NIH's mission to expand the medical knowledgebase to reduce the burden of human disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
High Priority, Short Term Project Award (R56)
Project #
2R56HL094740-06A1
Application #
8903582
Study Section
Hemostasis and Thrombosis Study Section (HT)
Program Officer
Sarkar, Rita
Project Start
2014-09-01
Project End
2015-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
6
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Pathology
Type
Schools of Medicine
DUNS #
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Foley, Jonathan H; Walton, Bethany L; Aleman, Maria M et al. (2016) Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin. EBioMedicine 5:175-82
Byrnes, James R; Wilson, Clare; Boutelle, Anthony M et al. (2016) The interaction between fibrinogen and zymogen FXIII-A2B2 is mediated by fibrinogen residues γ390-396 and the FXIII-B subunits. Blood 128:1969-1978
Byrnes, James R; Wolberg, Alisa S (2016) Newly-Recognized Roles of Factor XIII in Thrombosis. Semin Thromb Hemost 42:445-54
Wolberg, Alisa S (2016) Primed to Understand Fibrinogen in Cardiovascular Disease. Arterioscler Thromb Vasc Biol 36:4-6
Rautou, Pierre-Emmanuel; Tatsumi, Kohei; Antoniak, Silvio et al. (2016) Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury. J Hepatol 64:53-9
Geddings, J E; Hisada, Y; Boulaftali, Y et al. (2016) Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost 14:153-66
Wolberg, Alisa S; Rosendaal, Frits R; Weitz, Jeffrey I et al. (2015) Venous thrombosis. Nat Rev Dis Primers 1:15006
Wolberg, Alisa S; Levy, Jerrold H (2015) Editorial Comment: Factor XIII: One More Critical Factor for Hemostasis. A A Case Rep 4:125-6
Byrnes, James R; Duval, Cédric; Wang, Yiming et al. (2015) Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking. Blood 126:1940-8
Hur, Woosuk S; Mazinani, Nima; Lu, X J David et al. (2015) Coagulation factor XIIIa is inactivated by plasmin. Blood 126:2329-37

Showing the most recent 10 out of 15 publications